Mivavotinib citrate is under clinical development by Calithera Biosciences and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mivavotinib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mivavotinib citrate overview

Mivavotinib citrate (TAK-659) is under development for the treatment of gastric cancer and relapsed or refractory acute myelogenous leukemia (AML). It is administered through oral route. It acts by targeting Syk and FLT3 inhibitor. It was also under development for the treatment of advanced solid tumors such as colon cancer, ovarian cancer, pancreatic cancer, metastatic triple-negative breast cancer, metastatic non-small cell lung cancer, metastatic or recurrent head and neck squamous cell carcinoma, hematological malignancies including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma (iNHL), marginal zone lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, post-transplant lymphoproliferative disorder (PTLD) and mantle cell lymphoma.

Calithera Biosciences overview

Calithera Biosciences (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminase inhibitor in tumor metabolism to treat solid tumors, NCB001158, a small molecule arginase inhibitor based on tumor immunology technology that activates the body’s own immune system to attack and kill cancer cells for the treatment of hematology and oncology diseases, CB-280, a arginase inhibitor used for treating Cystic Fibrosis, CB-708, a CD73 inhibitor against immuno-oncology conditions and IL4I1 Inhibitor CB-668 against immuno-oncology conditions. The company works in collaboration with bio-pharmaceutical companies such as Incyte Corp, Bristol-Myers Squibb (BMS), and Mars Symbiosciences Inc. Calithera is headquartered in South San Francisco, California, the US.

For a complete picture of Mivavotinib citrate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.